SOSV

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataract surgery in both the human and veterinary markets.

Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses have evolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataract surgery in both the human and veterinary markets.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Mazlite is a developer of an industrial IoT platform focused on spray monitoring and digitization in hazardous environments. The company provides unique hardware sensors and web-based software that facilitate real-time analytics and cloud-based data management. This technology is particularly beneficial for industries such as automotive paint and pharmaceuticals, allowing manufacturers to monitor spray applications effectively. By utilizing a physics-based artificial intelligence system, Mazlite enables manufacturers to identify and resolve product quality issues, enhance sustainability, and reduce material and energy waste, ultimately minimizing scraps and repairs.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Spindle Biotech Inc., founded in 2017 and based in Toronto, Canada, specializes in the development of synthetic RNA. The company is focused on commercializing a proprietary RNA polymerase that facilitates large-scale production of mRNA vaccines. Recent advancements in mRNA technology underscore the significance of synthetic RNA, particularly for its transient properties. Spindle Biotech also employs enzymes and microfluidic technology to create high-fidelity RNA arrays, which are designed for high-throughput applications in RNP-based CRISPR and RNA screening. These innovations enable biotechnology companies to utilize synthetic RNA in gene editing and drug discovery, positioning Spindle Biotech as a key player in the evolving landscape of biotechnology.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Bioeutectics focuses on creating environmentally friendly industrial products by providing high-performance, natural solvents. Utilizing proprietary eutectic technology, the company produces solvents that mimic the natural processes of plants, using 100% renewable resources. This innovation allows Bioeutectics to replace traditional petrochemical solvents in various industrial applications, promoting sustainability. Their product line caters to diverse sectors, including food, pharmaceuticals, and personal care, and is designed to be non-toxic, biodegradable, and customizable to meet specific industry needs. Through these advancements, Bioeutectics aims to lead the market in offering sustainable alternatives that enhance environmental responsibility in industrial processes.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

RxAll is a Deep Learning-Hyperspectral IoT Platform for instant authentication and real-time global tracking of quality of drugs- prescription & OTC meds., opioids, recreational drugs and cannabis- through mobile phones and a cloud based platform. We deliver authenticated medicines to hospitals, pharmacies and patients.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

RxAll is a Deep Learning-Hyperspectral IoT Platform for instant authentication and real-time global tracking of quality of drugs- prescription & OTC meds., opioids, recreational drugs and cannabis- through mobile phones and a cloud based platform. We deliver authenticated medicines to hospitals, pharmacies and patients.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

ANA Therapeutics Inc. is a biotechnology company focused on the research and development of niclosamide-based vaccines and therapeutics aimed at treating COVID-19. Founded in 2020 and headquartered in Foster City, California, the company is developing a proprietary formulation of niclosamide, which is designed to help medical practitioners effectively treat patients afflicted with the coronavirus. ANA Therapeutics is actively conducting human clinical trials to evaluate the efficacy of its product, ANA001, which comes in the form of capsules. The company's mission is to address the challenges posed by the coronavirus pandemic and contribute to patient care and recovery.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

Brightcure is solving the lack of treatment options available for patients suffering from recurrent urinary tract infections (UTIs). UTIs are one of world’s most common infections, affecting 50% of women and 12% of men worldwide. Current UTI treatments are not effective, can cause serious side effects, and often accelerate antibiotic-resistant infections. Total UTI costs currently amount over $ 8.6B per year. With UTI bacteria becoming increasingly difficult to treat, the size of the UTI market is expected to reach $ 12.41B by 2025. Brightcure utilizes the natural microbiome to reduce harmful bacteria and replenish the good bacteria in the vaginal flora. Brightcure’s bioactive intimate cream boosts the natural immune system to promote a healthy urinary tract. BrightCure was founded in 2019 and is headquartered in London, England. In 2020, BrightCure got a seed investment from SOSV and was selected as 1 out of 9 companies to be part of the world's largest biotech accelerator, Indiebio, to develop its first product. BrightCure has been selected as one of the Top 7 companies of the McKinsey Venture Challenge, Top 5 of the Mayor of London Competition, has won Imperial College's White City Innovation Program, and has taken part in the finals of ‘The Pitch’ London Competition being selected among 850 other applications.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

ANA Therapeutics Inc. is a biotechnology company focused on the research and development of niclosamide-based vaccines and therapeutics aimed at treating COVID-19. Founded in 2020 and headquartered in Foster City, California, the company is developing a proprietary formulation of niclosamide, which is designed to help medical practitioners effectively treat patients afflicted with the coronavirus. ANA Therapeutics is actively conducting human clinical trials to evaluate the efficacy of its product, ANA001, which comes in the form of capsules. The company's mission is to address the challenges posed by the coronavirus pandemic and contribute to patient care and recovery.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

RxAll is a Deep Learning-Hyperspectral IoT Platform for instant authentication and real-time global tracking of quality of drugs- prescription & OTC meds., opioids, recreational drugs and cannabis- through mobile phones and a cloud based platform. We deliver authenticated medicines to hospitals, pharmacies and patients.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Bioprocol is a company founded in 2004 that specializes in producing natural materials derived from ethically sourced plants within Colombia's rich biodiversity. Utilizing scientifically validated methods, Bioprocol develops raw materials for the pharmaceutical, cosmetic, and nutraceutical industries. The company's offerings are aimed at enhancing health, beauty, and well-being, particularly through the creation of skincare products designed to restore and improve skin quality. By focusing on sustainable practices, Bioprocol not only supports the conservation of Colombian biodiversity but also contributes to the development of high-value innovations in various sectors.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

CyCa OncoSolutions Pvt. Ltd. is a technology company focused on developing molecular devices for the targeted delivery of anticancer drugs directly into cells. Established in 2017 and based in Balasore, India, the company has created innovative drug delivery systems that can cross cellular membrane bilayers, facilitating the introduction of functional molecules such as anticancer agents, water-soluble dyes, and imaging agents into the cytoplasm and other organelles. This technology is particularly beneficial for pharmaceutical and biotechnology companies, as it enhances the brand lifecycle of their drugs and molecules by improving delivery efficacy.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataract surgery in both the human and veterinary markets.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

NewPath Probiotics is a Chicago-based company that specializes in manufacturing probiotic medicine specifically designed for the treatment of sinus-related issues. Founded in 2018, the company offers a product known as New Path Probiotics Sinus Rinse, which aims to alleviate symptoms associated with sinus problems and address sinus microbes. By focusing on organic and natural ingredients, NewPath Probiotics provides an alternative to traditional over-the-counter nasal steroids, allowing customers to manage congestion through a more natural approach.

CyCa OncoSolutions Pvt. Ltd. is a technology company focused on developing molecular devices for the targeted delivery of anticancer drugs directly into cells. Established in 2017 and based in Balasore, India, the company has created innovative drug delivery systems that can cross cellular membrane bilayers, facilitating the introduction of functional molecules such as anticancer agents, water-soluble dyes, and imaging agents into the cytoplasm and other organelles. This technology is particularly beneficial for pharmaceutical and biotechnology companies, as it enhances the brand lifecycle of their drugs and molecules by improving delivery efficacy.

Size matters, or rather the uniformity of microparticles makes a big difference. A difference, for example, that can allow an eye surgery to become a outpatient event. MicroSpray technologies are making this a reality by decreasing the size of the drugs into uniform microspheres, which you can then inject into the eye with the smallest gauge needle rather than a more invasive tool. Currently, biopharmaceutical industries use costly chemical methods to manufacture microspheres, which rely on batch-type processes, have a low throughput and produce non-uniform particles. MicroSpray Technologies is developing a spray-manufacturing system which enables reproducible, tight and uniform control of particle size. Allowing clinicians to administer control over the rate at which drugs are delivered to patients, using novel slow release particle technologies.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataract surgery in both the human and veterinary markets.

MezoMax, Inc. is a biotechnology company based in San Francisco, California, founded in 2017. It specializes in developing oral therapies for nonhealing fractures and bone-related diseases, focusing on enhancing fracture healing and treating osteoporosis, particularly in elderly patients. The company’s innovative product features a novel calcium gluconate stereoisomer that regulates calcium and mineral metabolism, facilitating faster osteogenesis. By stimulating bone-forming cells, MezoMax's small molecule drug offers a safer and more effective approach to bone repair, enabling healthcare professionals to improve patient outcomes in the management of fractures and rare bone diseases.

Nivien Therapeutics developed the first small molecule inhibitors of the Hippo signaling pathway. Read the Nivien story in The Washington Post: https://www.washingtonpost.com/national/health-science/heres-what-happened-when-i-tried-to-develop-a-new-drug-for-a-deadly-cancer/2019/01/11/

Cell-Free Technology Limited, established in 2017 and located in Cork, Ireland, specializes in the production of cell-free extracts that enable the synthesis of essential biomolecules, such as insulin, odors, bio-compatible color palettes, and fluorescent proteins. This innovative approach allows for cell-free protein expression, facilitating the creation of biological products without the constraints of traditional laboratory settings or regulations related to genetic modification. The company offers ultra low-cost cell-free extracts and kits designed to simplify biological production, making it accessible for various applications outside conventional labs. Additionally, Cell-Free Technology is committed to open-source projects, actively sharing resources to promote wider use and understanding of their technology.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Neurocarrus Inc. is a biotechnology company based in Lincoln, Nebraska, focused on developing innovative drug delivery technologies to address pain management. Established in 2017, the company has created a non-opioid therapeutic, N-001, which utilizes protein engineering to target sensory neurons and effectively "freeze" pain signals before they reach the brain. Laboratory and animal studies suggest that N-001 offers comparable pain relief to opioids while lasting longer, positioning it as a vital alternative amid the ongoing opioid crisis. This novel approach aims to enhance the quality of life for individuals suffering from chronic pain, particularly those with tissue injuries, inflammation, or acute nerve damage. Furthermore, Neurocarrus holds exclusive rights to its drug and delivery system, which may also serve as a platform for future partnerships and therapeutic developments related to sensory neuron needs.

Scaled Biolabs Inc. is a biotechnology company founded in 2016 and based in San Francisco, California, specializing in research and development solutions for cell therapies. The company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to enable biotech and pharmaceutical firms to explore numerous parameters across extensive experimental processes. This innovative platform allows for the simultaneous execution of multiple experiments in a miniaturized lab setting, leading to deeper biological insights and the identification of optimal conditions for cellular processes. Scaled Biolabs also engages in the internal development of cell therapy assets, including a program focused on induced pluripotent stem cell-derived dopaminergic neurons for treating Parkinson's disease. Through its technologies, Scaled Biolabs aims to streamline the manufacturing process of complex medicines, reduce time to market, and enhance clinical outcomes for patients.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Hyasynth is a bioengineering company focused on producing cannabinoid products through precision fermentation, significantly reducing the environmental impact associated with the traditional cultivation of plants. By employing a scalable and cost-efficient fermentation process, Hyasynth eliminates over 97% of the carbon footprint typically associated with the CBD market, which is valued at $12 billion globally. Their innovative approach combines traditional and modern biological techniques with computational insights to develop organisms designed to address various health issues, such as multiple sclerosis, epilepsy, and Alzheimer's disease. This technology allows for the creation of regulatory-compliant products aimed at improving patient health without the need for plant cultivation.

Proteorex Therapeutics Inc. is a biotechnology company focused on developing novel therapeutics for diseases with significant unmet medical needs. Founded in 2014 and headquartered in Toronto, Canada, the company specializes in the creation of small molecule drugs targeting challenging and previously undruggable biological pathways. Utilizing a proprietary platform that integrates innovative synthesis design, computational modeling, and patient-derived cell-based screening, Proteorex aims to expedite the drug discovery process while reducing costs. The company's research primarily emphasizes oncology, leveraging protein-protein interactions to identify and develop new therapeutic candidates. Additionally, Proteorex operates an office in San Francisco, enhancing its reach and collaboration potential within the biotechnology landscape.

Cell-Free Technology Limited, established in 2017 and located in Cork, Ireland, specializes in the production of cell-free extracts that enable the synthesis of essential biomolecules, such as insulin, odors, bio-compatible color palettes, and fluorescent proteins. This innovative approach allows for cell-free protein expression, facilitating the creation of biological products without the constraints of traditional laboratory settings or regulations related to genetic modification. The company offers ultra low-cost cell-free extracts and kits designed to simplify biological production, making it accessible for various applications outside conventional labs. Additionally, Cell-Free Technology is committed to open-source projects, actively sharing resources to promote wider use and understanding of their technology.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative treatments for incurable cancers and neurodegenerative diseases. Founded in 2017 and based in San Diego, California, the company utilizes a machine vision and learning platform to drive diseased stem cells toward non-diseased states. Its proprietary technology, known as microscopic imaging of epigenetic landscapes (MIEL), facilitates the discovery of small molecules that can induce epigenetic changes, allowing for the differentiation or reversal of cancerous cells into benign types, which holds potential for curative outcomes. Additionally, Stelvio is pursuing a personalized approach to glioblastoma treatment, leveraging its team's expertise in scientific innovation and clinical management to advance novel drug therapies and precision medicine diagnostics.

PSG Therapeutics

SwaLife Biotech discovers small molecules from plants for cosmetics and synthesizes novel anticancer plant alkaloids for medical use targeting DNA damage response.

CyCa OncoSolutions Pvt. Ltd. is a technology company focused on developing molecular devices for the targeted delivery of anticancer drugs directly into cells. Established in 2017 and based in Balasore, India, the company has created innovative drug delivery systems that can cross cellular membrane bilayers, facilitating the introduction of functional molecules such as anticancer agents, water-soluble dyes, and imaging agents into the cytoplasm and other organelles. This technology is particularly beneficial for pharmaceutical and biotechnology companies, as it enhances the brand lifecycle of their drugs and molecules by improving delivery efficacy.

Hemoalgae is a biotechnology company based in Cartago, Costa Rica, established in 2016. It specializes in the production of hirudin, a natural anticoagulant derived from an improved microalgae strain. This innovative process enables the generation of valuable compounds that have significant medical applications, including treatment for coronary ischemic syndromes, disseminated intravascular coagulation, and thrombosis prophylaxis in both preoperative and postoperative settings. By leveraging genetic engineering tools, Hemoalgae aims to provide sustainable and cost-effective alternatives to traditionally sourced proteins and compounds, such as hirudin, which is typically obtained from leeches. The company's focus on microalgae positions it as a leader in developing bio-based solutions in the biotechnology sector.

Canuevo is developing drug delivery mechanisms for cannabinoid formulations to increase delivery efficacy. The company's drug delivery platforms are specifically designed to achieve the highest efficacy for particular chronic syndroms and conditions. They try to address the lack of standardization and acceptance of cannabis derived medication within the medical and regulatory community. Illnesses and conditions targeted by Canuevo's platforms include IBS, basal skin carcinoma, epilepsy, support medication for treating opiate dependency and pain regulation. Canuevo was started by Nils Rehmann, PhD and Daniel Carbo, MEng.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Venomyx, Inc. is a San Diego-based company founded in 2015 that specializes in the development and marketing of snake antivenom for the treatment of snakebites. The company aims to revolutionize antivenom treatment by introducing the world’s first toxin-specific snake antivenom, which is designed to enhance safety, efficacy, and affordability for the millions of individuals affected by snakebites annually. Venomyx addresses the critical needs of a largely underserved population, striving to improve outcomes for snakebite victims globally.

Scaled Biolabs Inc. is a biotechnology company founded in 2016 and based in San Francisco, California, specializing in research and development solutions for cell therapies. The company has developed a Cell Therapy Discovery Engine that leverages microfluidics, automation, and machine learning to enable biotech and pharmaceutical firms to explore numerous parameters across extensive experimental processes. This innovative platform allows for the simultaneous execution of multiple experiments in a miniaturized lab setting, leading to deeper biological insights and the identification of optimal conditions for cellular processes. Scaled Biolabs also engages in the internal development of cell therapy assets, including a program focused on induced pluripotent stem cell-derived dopaminergic neurons for treating Parkinson's disease. Through its technologies, Scaled Biolabs aims to streamline the manufacturing process of complex medicines, reduce time to market, and enhance clinical outcomes for patients.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, focused on developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. Established in 2016, the company utilizes a unique computational design platform called SCULPT™, which integrates experimentally determined target characteristics to systematically create therapeutic candidates. A2A Pharmaceuticals employs advanced therapeutic design methodologies to inhibit protein-protein interactions and applies bioinformatics tools specifically for gram-negative bacterial species. In addition to drug development, the company also provides consulting services aimed at enhancing healthcare professionals' abilities to treat complex diseases.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and based in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that leverages proprietary nanoparticles with a unique multilayered structure. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's drug delivery systems are designed to enhance the specificity, efficacy, and safety of cancer treatments, providing healthcare providers with improved tools for targeted therapy.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, focused on developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. Established in 2016, the company utilizes a unique computational design platform called SCULPT™, which integrates experimentally determined target characteristics to systematically create therapeutic candidates. A2A Pharmaceuticals employs advanced therapeutic design methodologies to inhibit protein-protein interactions and applies bioinformatics tools specifically for gram-negative bacterial species. In addition to drug development, the company also provides consulting services aimed at enhancing healthcare professionals' abilities to treat complex diseases.

Venomyx, Inc. is a San Diego-based company founded in 2015 that specializes in the development and marketing of snake antivenom for the treatment of snakebites. The company aims to revolutionize antivenom treatment by introducing the world’s first toxin-specific snake antivenom, which is designed to enhance safety, efficacy, and affordability for the millions of individuals affected by snakebites annually. Venomyx addresses the critical needs of a largely underserved population, striving to improve outcomes for snakebite victims globally.